<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Polyrizon Ltd. Ordinary Shares — News on 6ix</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares</link>
<description>Latest news and press releases for Polyrizon Ltd. Ordinary Shares on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 13:28:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/polyrizon-ltd-ordinary-shares" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ae2178dffbe2df10eb59.webp</url>
<title>Polyrizon Ltd. Ordinary Shares</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares</link>
</image>
<item>
<title>Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-announces-filing-of-european-patent-application-for-its-breakthrough-drug-delivery-platform</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-announces-filing-of-european-patent-application-for-its-breakthrough-drug-delivery-platform</guid>
<pubDate>Mon, 27 Apr 2026 13:28:00 GMT</pubDate>
<description>Raanana, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a divisional patent application with the Europe Patent Office for its Trap & Target (T&T) platform technology. This application focuses exclusively on protecting the Company’s advanced intranasal drug delivery system, which is designed to enhance the e</description>
</item>
<item>
<title>Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-ltd-announces-closing-of-dollar35-million-registered-direct-and-private-placements</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-ltd-announces-closing-of-dollar35-million-registered-direct-and-private-placements</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>RAANANA, ISRAEL, April 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a pre-clinical-stage biotechnology company developing</description>
</item>
<item>
<title>Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-ltd-announces-dollar35-million-registered-direct-offering-and-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-ltd-announces-dollar35-million-registered-direct-offering-and-private-placement</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>RAANANA, ISRAEL, April 07, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a pre-clinical-stage biotechnology company developing</description>
</item>
<item>
<title>Polyrizon Provides 2025 and Recent Highlights</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-provides-2025-and-recent-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-provides-2025-and-recent-highlights</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Company Concluded 2025 with Robust Cash Position, Debt-Free Balance Sheet and Significant Pipeline Achievements Raanana, Israel, March 26, 2026 (GLOBE</description>
</item>
<item>
<title>Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-ltd-files-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2025</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-ltd-files-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2025</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>Raanana, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company</description>
</item>
<item>
<title>Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-intends-to-acquire-up-to-20percent-stake-in-colugo-developer-of-advanced-evtol-drones-for-defense-and-urban-air-mobility-applications</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-intends-to-acquire-up-to-20percent-stake-in-colugo-developer-of-advanced-evtol-drones-for-defense-and-urban-air-mobility-applications</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>The Company signed a non-binding MOU with shareholders of Colugo. Colugo’s customer include the Israel Defense Forces, national first responders organizations</description>
</item>
<item>
<title>Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-signs-an-agreement-with-leading-global-preclinical-cro-as-part-of-clinical-development-program</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-signs-an-agreement-with-leading-global-preclinical-cro-as-part-of-clinical-development-program</guid>
<pubDate>Tue, 17 Mar 2026 12:25:00 GMT</pubDate>
<description>Raanana, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the signing of an agreement with a leading global preclinical Contract Research Organization (CRO), a recognized expert in biocompatibility and regulatory-compliant testing. This agreement forms part of Polyrizon's ongoing efforts to advance its clinical development program, whic</description>
</item>
<item>
<title>Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-announces-gmp-manufacturing-of-clinical-trial-material-ctm-with-eurofins-cdmo-amatsiaquitaine-sas-for-planned-us-clinical-study-3</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-announces-gmp-manufacturing-of-clinical-trial-material-ctm-with-eurofins-cdmo-amatsiaquitaine-sas-for-planned-us-clinical-study-3</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Raanana, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company</description>
</item>
<item>
<title>Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-announces-successful-study-of-its-naloxone-formulation-demonstrating-enhanced-nasal-deposition-profile-versus-commercial-reference-product</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-announces-successful-study-of-its-naloxone-formulation-demonstrating-enhanced-nasal-deposition-profile-versus-commercial-reference-product</guid>
<pubDate>Thu, 26 Feb 2026 13:12:00 GMT</pubDate>
<description>Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced results from a comparative study evaluating the regional nasal deposition profile of its naloxone formulation versus a commercial reference product. The study was conducted at the University of Parma’s Biopharmanet-TEC research center under the scientific supervision of Prof. Fabi</description>
</item>
<item>
<title>Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/moonage-media-spotlights-polyrizon-nasdaq-163200418</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/moonage-media-spotlights-polyrizon-nasdaq-163200418</guid>
<pubDate>Tue, 17 Feb 2026 16:32:00 GMT</pubDate>
<description>Early in 2026, Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, completed the branding process for its lead intranasal allergy product, formerly known as PL-14, now officially named NASARIX™. This included trademark screening in the U.S. and European markets and represents a practical step toward potential commercialization for the pre-clinical-stage Israeli biotech.</description>
</item>
<item>
<title>Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-intends-secure-controlling-stake-115500864</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-intends-secure-controlling-stake-115500864</guid>
<pubDate>Tue, 10 Feb 2026 11:55:00 GMT</pubDate>
<description>The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted EBITDA Raanana, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, recently announced the signing of a non-binding Memorandum of Understanding (MOU) with Arrow A</description>
</item>
<item>
<title>Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-signs-agreement-develop-intranasal-125500384</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-signs-agreement-develop-intranasal-125500384</guid>
<pubDate>Fri, 06 Feb 2026 12:55:00 GMT</pubDate>
<description>Collaboration aims to leverage Polyrizon’s advanced proprietary intranasal delivery platform to support clinical development of Clearmind’s drug candidate proprietary MEAI Raanana, Israel, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has entered into a development agreement with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”), a cl</description>
</item>
<item>
<title>Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-intends-acquire-51-stake-121200501</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-intends-acquire-51-stake-121200501</guid>
<pubDate>Wed, 04 Feb 2026 12:12:00 GMT</pubDate>
<description>The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted EBITDA Raanana, Israel, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the signing of a non-binding Memorandum of Understanding (MOU) with Arrow Avia</description>
</item>
<item>
<title>Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-advances-regulatory-path-initiation-142500252</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-advances-regulatory-path-initiation-142500252</guid>
<pubDate>Thu, 22 Jan 2026 14:25:00 GMT</pubDate>
<description>Executed in accordance with FDA human factors and usability engineering guidance, the study is intended to de-risk downstream regulatory review and support a streamlined path toward clinical development Raanana, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the initiation of a key usability (Human Factors) study program for its lead prod</description>
</item>
<item>
<title>Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-explore-revenue-generating-investment-133900912</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-explore-revenue-generating-investment-133900912</guid>
<pubDate>Tue, 13 Jan 2026 13:39:00 GMT</pubDate>
<description>Company Remains Fully Committed to Advancing Its Core Intranasal Medical Pipeline, alongside examining new opportunities including in fields of aviation, AI and defense Raanana, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, recently announced that its Board of Directors has authorized the exploration of strategic investment opportunities</description>
</item>
<item>
<title>Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-completes-branding-process-pl-134500833</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-completes-branding-process-pl-134500833</guid>
<pubDate>Thu, 08 Jan 2026 13:45:00 GMT</pubDate>
<description>As part of the branding process, Polyrizon conducted comprehensive trademark screening across the U.S. and European markets Raanana, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has completed the branding process for its PL-14 allergy blocker, which will be marketed under the brand name NASARIX™. NASARIX™ is based</description>
</item>
<item>
<title>Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-announces-pre-clinical-results-140700081</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-announces-pre-clinical-results-140700081</guid>
<pubDate>Mon, 05 Jan 2026 14:07:00 GMT</pubDate>
<description>Raanana, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from a new in-vitro pre-clinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation compared to hydroxypropyl methylcellulose (HPMC), an accepted and standard comparator used in nasal barrier products. The study,</description>
</item>
<item>
<title>As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/flu-surge-continues-polyrizons-nasal-133000211</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/flu-surge-continues-polyrizons-nasal-133000211</guid>
<pubDate>Fri, 02 Jan 2026 13:30:00 GMT</pubDate>
<description>Raanana, Israel, Jan. 02, 2026 (GLOBE NEWSWIRE) -- As the 2025-2026 flu season intensifies across the United States, a mutated strain of influenza A is driving most cases, sparking concerns about a potentially tough winter ahead. According to the latest CDC estimates (as of late December 2025), flu has already caused at least 4.6 million illnesses, 49,000 hospitalizations, and 1,900 deaths nationwide. Flu activity is rising sharply, with outpatient visits for influenza-like illness well above ba</description>
</item>
<item>
<title>Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-explore-revenue-generating-real-122000821</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-explore-revenue-generating-real-122000821</guid>
<pubDate>Mon, 29 Dec 2025 12:20:00 GMT</pubDate>
<description>Company to Continue Advancing Product Development and Regulatory Progress of Its Core Medical Pipeline Raanana, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that its Board of Directors has decided to explore realistic investment opportunities in revenue-generating real assets. The Company remains fully committed to its co</description>
</item>
<item>
<title>Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses</title>
<link>https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-submits-pre-request-designation-132000455</link>
<guid isPermaLink="true">https://6ix.com/company/polyrizon-ltd-ordinary-shares/news/polyrizon-submits-pre-request-designation-132000455</guid>
<pubDate>Fri, 19 Dec 2025 13:20:00 GMT</pubDate>
<description>The PL-16 Viral Blocker has shown over 90% success in protection of cells against viruses Raanana, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd., a pre-clinical-stage biotechnology company developing intranasal protective solutions, announced today that it has submitted a Pre-Request for Designation (Pre-RFD) to the U.S. Food and Drug Administration (FDA) for its PL-16 Viral Blocker, a non-pharmacological intranasal product designed to reduce exposure to airborne respiratory viruses,</description>
</item>
</channel>
</rss>